Comparison between optimized bismuth quadruple therapy and standard clarithromycin-based triple therapy for first-line Helicobacter pylori eradication: a double-blind randomized controlled trial.

Medel-Jara PA, Latorre G, Fuentes-Lopez E, Pizarro M, Viviani P, Chahuán J, Maquilón S, Corsi O, Reyes D, Espino A, Vargas JI, Wichmann IA, Harris P, Serrano C, Buruato I, Sandoval C, Varela NM, Cerpa L, Quiñones L, Megraud F, Huang RJ, Shah SC, Perez AR

Open source

DOI: 10.1016/j.lana.2025.101312
Published: 2026 Jan
Container: Lancet regional health. Americas
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.lana.2025.101312,
  title = {Comparison between optimized bismuth quadruple therapy and standard clarithromycin-based triple therapy for first-line Helicobacter pylori eradication: a double-blind randomized controlled trial.},
  author = {Medel-Jara PA and Latorre G and Fuentes-Lopez E and Pizarro M and Viviani P and Chahuán J and Maquilón S and Corsi O and Reyes D and Espino A and Vargas JI and Wichmann IA and Harris P and Serrano C and Buruato I and Sandoval C and Varela NM and Cerpa L and Quiñones L and Megraud F and Huang RJ and Shah SC and Perez AR},
  year = {2026},
  journal = {Lancet regional health. Americas},
  doi = {10.1016/j.lana.2025.101312},
  url = {https://doi.org/10.1016/j.lana.2025.101312}
}

RIS

TY  - JOUR
TI  - Comparison between optimized bismuth quadruple therapy and standard clarithromycin-based triple therapy for first-line Helicobacter pylori eradication: a double-blind randomized controlled trial.
AU  - Medel-Jara PA
AU  - Latorre G
AU  - Fuentes-Lopez E
AU  - Pizarro M
AU  - Viviani P
AU  - Chahuán J
AU  - Maquilón S
AU  - Corsi O
AU  - Reyes D
AU  - Espino A
AU  - Vargas JI
AU  - Wichmann IA
AU  - Harris P
AU  - Serrano C
AU  - Buruato I
AU  - Sandoval C
AU  - Varela NM
AU  - Cerpa L
AU  - Quiñones L
AU  - Megraud F
AU  - Huang RJ
AU  - Shah SC
AU  - Perez AR
PY  - 2026
JO  - Lancet regional health. Americas
DO  - 10.1016/j.lana.2025.101312
UR  - https://doi.org/10.1016/j.lana.2025.101312
ER  -

APA

PA, M., G, L., E, F., M, P., P, V., J, C., S, M., O, C., D, R., A, E., JI, V., IA, W., P, H., C, S., I, B., C, S., NM, V., L, C., L, Q., F, M., RJ, H., SC, S., & AR, P. (2026). Comparison between optimized bismuth quadruple therapy and standard clarithromycin-based triple therapy for first-line Helicobacter pylori eradication: a double-blind randomized controlled trial.. Lancet regional health. Americas. https://doi.org/10.1016/j.lana.2025.101312

Source records

pubmed · retrieved 2026-09-27T00:45:47.694Z
europe-pmc · retrieved 2026-09-27T00:45:47.703Z